National health statistics were not designed to measure the core competency established in Phase One. They measure disease burden, utilization, costs, products, procedures, and episodes of care. These numbers can describe the scale of a problem or the performance of a specific intervention. They do not tell us whether a care team can understand a patient, hold the full clinical arc, and produce meaningful improvement over time.
That distinction matters. A statistic can be accurate and still be inadequate for the argument being made. Cost-of-illness data can show that a condition is expensive, but not whether your model can address it. Cost-effectiveness measures can establish the value of a drug, test, device, or protocol while leaving the delivery of care itself largely unmeasured. National averages can provide context, but they cannot substitute for the actual population, costs, capacity, and patterns of use present within a specific cooperative.
Further, some statistics are routinely repeated as claims they do not actually support. One of the most repeated numbers in US healthcare says that 90 percent of the nation’s $5.3 trillion in annual health expenditures is associated with people who have chronic or mental health conditions. It is commonly heard and increasingly repeated as though 90 percent of healthcare spending goes toward treating chronic disease.
It does not. 90% Problem
Many attempts to change healthcare reach their decisive moment carrying this same weakness: a case built from numbers that were never designed to assess the model’s core competency.
What this actually requires: Phase One establishes the core competency: health care exists only in the relationship between the patient and the care team responsible for them. Phase Two determines how to measure what happens there to make sure health care is delivered.
This is not a rejection of conventional health statistics. It is recognition of their limits. A measurement system organized around products and episodes will continue to credit the product, count the episode, and leave the relationship largely invisible — even when that relationship is what recognized the pattern, selected the intervention, supported its use, adjusted the plan, and carried the patient toward recovery.
The development process must therefore define the model's own measures of success before a funder, board, employer, or skeptic asks for evidence. Those measures should make the core competency visible.
Engagement must be tracked over time — not simply as visits completed, but as evidence that a functioning relationship exists and is being supported so it can be sustained. Clinical progress must include both subjective and objective measures, because health includes how patients experience their lives and what they are demonstrably able to do. Outcomes should be measured against the patient’s own baseline, needs, and potential rather than against an abstract standard patient.
The model must also establish a real financial baseline. Cost trends should be compared with the anchor population’s own historical spending, utilization, absenteeism, disability, and other relevant measures, rather than relying only on national averages that may describe a substantially different population. The time horizon must be long enough to capture what continuous care is intended to produce: stabilization, recovery, greater capacity, fewer preventable escalations, and less dependence on repeated episodic intervention.
The clinical model, fee structure, and measurement plan must be designed together. Measurement cannot be added later as a reporting requirement. What the organization chooses to count will influence what it builds, funds, and sustains.
The central test is straightforward: Does the measurement system assess what is happening between the patient and the care team, or does it merely count the structures and products surrounding them?
A plan that waits until someone demands evidence has already allowed someone else’s metrics to define what success means.
Target Endpoint: A measurement framework written directly into the business plan, with defined clinical, engagement, capacity, utilization, and cost measures; a specific baseline and comparator; and a timeline long enough to assess the full arc of care.
The framework should stand on its own before anyone asks for it and it must be capable of measuring the model’s core competency in the only place health care actually exists: between the patient and their care team.